Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension.

Li‐Saw‐Hee, Foo Leong; Edmunds, E.; Blann, Andrew D.; Beevers, D. G.; Lip, Gregory Y.H.

doi:10.1016/s0167-5273(00)00274-6

Cited by 89 publications

(65 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, this result is in contrast with a previous clinical trial that did not demonstrate an ability of losartan to decrease MMP-9 in hypertensive, non-diabetic subjects by leveraging AT1 inhibition. 44 The reason for this disagreement may be because of the shorter period of administration of antihypertensive drugs in the study by Li-Saw-Hee 44 (2 months) compared with our study in which losartan or ramipril was administered for 14 months.…”

Section: Correlationsmentioning

confidence: 57%

Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients

et al. 2010

View full text Add to dashboard Cite

We planned a randomized, double blind clinical trial to evaluate whether an antihypertensive intervention at the proximal or distal level of the renin-angiotensin-aldosterone system could have different effects on a broad range of innovative cardiovascular risk biomarkers. A total of 288 hypertensive Caucasian patients (115 men and 113 women), aged X18 years, were enrolled in this study. They were randomized to take losartan 50 mg per day or ramipril 5 mg per day for 1 month and titrated up to 100 mg per day and 10 mg per day for 13 months, respectively. At baseline, 1, 2 and 14 months after therapy initiation, we evaluated the following parameters: body weight, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting plasma glucose (FPG), M-value, adiponectin (ADN), resistin (r), retinol binding protein-4 (RBP-4), visfatin, vaspin, high-sensitivity C-reactive protein (Hs-CRP), matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). No variation of body weight, BMI, FPG or vaspin was obtained with either treatment. We recorded a similar improvement in SBP, DBP and Hs-CRP with both treatments; however, losartan also increased M-value, ADN and visfatin, whereas ramipril did not. Furthermore, losartan decreased r, RBP-4, MMP-2 and MMP-9, whereas ramipril did not have any effect on these parameters. In conclusion, we observed that short-term treatment with losartan improved several metabolic parameters (M-value, ADN, RBP-4, r and visfatin) and decreased vascular remodeling biomarkers (MMP-2 and MMP-9) in hypertensive subjects, whereas ramipril did not.

show abstract

Section: Correlationsmentioning

confidence: 57%

Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Laviades et al 11 have shown normalization of MMP-1 and TIMP-1 after 1-year treatment with the angiotensin-converting enzyme (ACE) inhibitor lisinopril. Conversely, Li-Saw-Hee et al 13 have recently reported that a short follow-up period (2 months) with antihypertensive treatment either with an ACE inhibitor enalapril or an angiotensin AT 1 receptor antagonist losartan did not alter significantly the levels of MMP-9 and TIMP-1. 13 Amlodipine has been demonstrated to increase the proteolytic activity of MMP-2 and to inhibit the transcription of TIMP-2 in both fibroblasts and vascular smooth muscle cells.…”

Section: Discussionmentioning

confidence: 93%

“…Conversely, Li-Saw-Hee et al 13 have recently reported that a short follow-up period (2 months) with antihypertensive treatment either with an ACE inhibitor enalapril or an angiotensin AT 1 receptor antagonist losartan did not alter significantly the levels of MMP-9 and TIMP-1. 13 Amlodipine has been demonstrated to increase the proteolytic activity of MMP-2 and to inhibit the transcription of TIMP-2 in both fibroblasts and vascular smooth muscle cells. 22 A possible regulatory mechanism of MMP-2 activation could be linked to changes of intracellular calcium concentration.…”

Section: Discussionmentioning

confidence: 93%

“…Brilla et al 12 have shown that the activity of MMP-1, but not MMP-9, was depressed in the left ventricle of hypertensives with LVH. 12 Recently, Li-Saw-Hee et al 13 reported that the proteolytic activities of MMP-9 and TIMP-1 are depressed in hypertensive patients. On the contrary, significant increases in MMP-1 and MMP-9 levels have been observed in aneurysmal aortic specimens.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, the proteolytic activities of MMP-9 and TIMP-1 have been suggested to be depressed in hypertensive patients. 13 Interstitial collagenase, MMP-1, is capable of degrading structural or fibrillar collagens (types I-III). Gelatinases A (MMP-2) and B (MMP-9) are two enzymes that mainly digest denatured collagen (gelatins), elastin, fibronectin, laminin as well as collagens type IV and V, mainly found in the subendothelial basement membrane of the vessel wall.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment

Zervoudaki¹,

Economou²,

Stefanadis³

et al. 2003

J Hum Hypertens

View full text Add to dashboard Cite

This study was designed to test the hypothesis that plasma concentrations of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9), two enzymes that share similar substrate specificity (collagen type IV and V), possibly related to vascular remodelling, are altered in essential hypertension. The second aim of the study was to assess whether chronic antihypertensive treatment with the calcium channel blocker amlodipine would normalize these alterations. To test this hypothesis, we measured plasma concentrations of active MMP-2 and MMP-9 in 42 patients with never-treated essential hypertension and in 25 normotensive control subjects. Measurements were repeated after 6 months of treatment with the calcium channel blocker amlodipine. Baseline values of MMP-2 and MMP-9 were decreased (P ¼ 0.01 and 0.002, respectively) in hypertensive patients compared with normotensives. Hypertensive patients with systemic vascular resistances o1440 dyn s/cm 5 exhibited higher values of MMP-2 (P ¼ 0.005) and MMP-9 (P ¼ 0.001) than hypertensive patients with systemic vascular resistances 41440 dyn s/cm 5 . Treated patients attained a nonsignificant increase in MMP-2 plasma concentrations, but a significant increase in MMP-9 plasma concentrations (P ¼ 0.01) compared to respective values before treatment. In conclusion, these findings suggest that plasma concentrations of active MMP-2 and MMP-9, mainly related to vascular extracellular matrix metabolism, are depressed in patients with essential hypertension. A 6 month treatment with amlodipine can normalize MMP-9 but not MMP-2 plasma concentrations. The hypothesis that antihypertensive treatment may modulate collagen metabolism remains to be determined by further studies.

show abstract

Matrix Metalloproteinases and Myocardial Remodeling

Chapman

Spinale

Developments in Cardiovascular Medicine

View full text Add to dashboard Cite

Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension.

Cited by 89 publications

References 14 publications

Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients

Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients

Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment

Matrix Metalloproteinases and Myocardial Remodeling

Contact Info

Product

Resources

About